MAPT and Alzheimer disease: This was defined as: “...individuals with biomarker designation of either AD or Alzheimer’s pathologic change”, wherein “biomarker designation of AD” refers to in vivo evidence of Aβ and tau pathology and “Alzheimer’s pathologic change” refers to in vivo evidence of Aβ pathology alone (with normal tau biomarkers).